

THE SHAREHOLDERS' MEETING OF SVAS BIOSANA S.p.A.***Approves the financial statements for the year ended 31 December 2023******Resolves the distribution of a dividend of € 0.30******Appoints the Board of Directors for 2024-2026******Appoints the Board of Statutory Auditors for 2024-2026******Resolution on the amendment of certain articles of the Articles of Association***

Somma Vesuviana (NA) 15 May 2024 – Svas Biosana S.p.A. (the “Group” or “SVAS”), a leading healthcare sector company, operating in the production and distribution of medical devices for public and private healthcare facilities, listed on Euronext Growth Milan – a multilateral trading system organized and managed by Borsa Italiana S.p.A. dedicated to small and medium-sized enterprises with high growth potential – announces that the Shareholders’ Meeting, which met today in first call in compliance with the provisions of Decree-Law no. 18/2020 and subsequent amendments - i.e. without its shareholders being in attendance in person, in an ordinary session, resolved on the financial statements as at 31 December 2023 and on the allocation of the profit for the year, deciding on the distribution of a dividend of € 0.30 per share. The Shareholders' Meeting also appointed the members of the Board of Directors and the Board of Statutory Auditors for the 2024-2026 financial years.

The Shareholders’ Meeting, which then met in an extraordinary session, approved some amendments to the Company’s Articles of Association.

ORDINARY SHAREHOLDERS’ MEETING**1) Approval of the Financial Statements as at 31 December 2023**

The Shareholders' Meeting approved the **financial statements** of the company Svas Biosana S.p.A. which generated **sales revenues** from operations of **€ 55.8 million (+0.7% YoY)**.

The **Production Value** is **€ 61.1 million**, an increase of **+1.2%** compared to 2022.

EBITDA is **€ 5.8 million**, down **1.6%** on the previous year.

EBIT amounts to **€ 2.1 million**, down **5.5%** compared to 2022.

Net Profit is **€ 1.1 million**, up **47.0%** on 2022.

The **Net Financial Position** is negative to the tune of **€ 23.1 million**.

The Shareholders’ Meeting also examined the Group’s **consolidated financial statements** for the 2023 financial year.

Revenues from operations as at 31 December 2023 amounted to **€ 118.3 million (+21.7% YoY)**.

The **Production Value** is **€ 122.3 million (+19.6% YoY)**.

EBITDA amounted to **€ 14.2 million**, up **19.7%** compared to 2022.

EBIT amounts to **€ 8.6 million**, up **36.9%** on 2022.

Net Profit is **€ 5.1 million (+43.5% compared to 2022)**.

The **Net Financial Position** is negative to the tune of **€ 23.8 million**.

SVAS BIOSANA S.p.A.

Registro Imprese di

Napoli n.4543/85

n. R.E.A. 393065

C.F. 04720630633

P. I.V.A. 01354901215

Sede Legale

Via M. Perillo, 34

80047

San Giuseppe Vesuviano (NA)

Italy

Corrispondenza

Casella Postale n.91

80049

Somma Vesuviana (NA)

Italy

Direzione ed Uffici

Via Trentola, 7

80049

Somma Vesuviana (NA)

Italy

Contatti

Tel. +390818995411

Fax +390818993922

www.svas.it

svasbiosana@legalmail.it

2) Proposed allocation of Operating Profit and part of available reserves

The Shareholders' Meeting resolved to allocate the profit for the year, **€1,118,380**, as follows:

- **€ 55,919** as legal reserve;
- **€ 1,062,461**, as dividends, along with a portion of the Extraordinary Reserve of up to **€ 541,390**, by distributing a gross ordinary dividend of € 0.30 for each qualifying ordinary share in circulation (excluding portfolio treasury shares) at the ex-dividend date.

The Shareholders' Meeting also decided that the **dividend payment date will be 29 May 2024**, with an **ex-dividend date of 27 May 2024** and a **record date of 28 May 2024**.

3) Appointment of the Board of Directors

The Shareholders' Meeting appointed the new Board of Directors – on the basis of the only list received from 21 Monte Somma S.r.l. – which will be in office for the next three financial years, until the date of the shareholders' meeting called to approve the financial statements for the year ending 31 December 2026, and established that the Board of Directors will have four members.

Specifically, the Shareholders' Meeting appointed Mr. Filippo Maraniello as Chairman of the Board of Directors, Mr. Umberto Perillo and Mr. Luigi Gatta as Directors, and Mr. Antonio Finocchi Ghersi as Independent Director.

Finally, the Ordinary Shareholders' Meeting also set gross total annual fees of € 260,000.00 (two hundred and sixty thousand) for the Board of Directors, that will be divided among the latter's members as determined by the Board itself, including fees for any directors who are vested with special tasks, including executive duties, pursuant to Article 2389, 1st and 3rd paragraphs, of the Italian Civil Code.

4) Appointment of the Board of Statutory Auditors

The Shareholders' Meeting also appointed the members of the Board of Statutory Auditors - on the basis of the only list received from 21 Monte Somma S.r.l. - who will be in office for the next three financial years, until the date of the shareholders' meeting called to approve the financial statements for the year ending 31 December 2026.

The Board of Statutory Auditors consists of Mr. Nicola Tino, Mr. Enrico Auriemma and Mr. Simone Vitobello as Standing Auditors; and Mr. Ciriaco Roberto Tino and Ms. Anna Camera as Alternate Auditors.

The annual remuneration payable to each standing auditor for the entire term of office was set as € 9,000 (nine thousand) plus VAT and charges as applicable, while the fee payable to the Chairman of the Board of Statutory Auditors will be € 12,000 (twelve thousand), plus VAT and charges as applicable.

EXTRAORDINARY SHAREHOLDERS' MEETING

All the amendments to the Articles of Association proposed to the Shareholders' Meeting today were approved by a majority of votes. It should be noted that, by way of a precautionary consideration by the Chairman of the Shareholders' Meeting, in relation to the last proposal (amending art. 16 of the Articles of Association) which triggers a termination clause, this was deemed to have occurred after a shareholder expressed their intention to withdraw. As such, the resolved amendment of art. 16 did not come into effect.

SVAS BIOSANA S.p.A.

Registro Imprese di
Napoli n.4543/85
n. R.E.A. 393065
C.F. 04720630633
P. I.V.A. 01354901215

Sede Legale

Via M. Perillo, 34
80047
San Giuseppe Vesuviano (NA)
Italy

Corrispondenza

Casella Postale n.91
80049
Somma Vesuviana (NA)
Italy

Direzione ed Uffici

Via Trentola, 7
80049
Somma Vesuviana (NA)
Italy

Contatti

Tel. +390818995411
Fax +390818993922
www.svas.it
svasbiosana@legalmail.it

* * * * *

The documentation required by the prevailing legislation for today's Shareholders' Meeting accompanied by the minutes of the Meeting (which also includes information on the number of shares represented at the Shareholders' Meeting and the results of the votes) will be made available to the public at the Company's headquarters, and will be available on the Company's website www.svas.it in the Investor Relations/Shareholders' Meeting section, and on the website of the Italian Stock Exchange www.borsaitaliana.it.

* * * * *

This press release is available at the Italian Stock Exchange, at the Group's registered office, and in the Investor Relations/Releases section [of www.svas.it](http://www.svas.it).

For the disclosure of regulated information Svas Biosana uses the eMarket SDIR circuit, which is managed by Teleborsa S.r.l., with headquarters in Piazza di Priscilla 4, 00199 Rome (www.emarketstorage.com).

Svas Biosana produces and distributes medical devices in Italy and abroad. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, SVAS is now an international player with a catalogue including about 16,000 own-brand and third-party products, with 350 employees, a dedicated Research and Development department, 3 production plants in Italy and subsidiaries in Slovenia, Croatia, Serbia and Bosnia and Herzegovina.

Ticker: ISIN Ordinary Shares: IT0005469264 Ticker: ISIN Warrant SVAS BIOSANA 2021-2024: IT0005469157

Contacts:

SVAS Biosana S.p.A.

Andrea Efficace
Group CFO and Investor Relations Manager
+39 081.8995411
a.efficace@svas.it

Investor Relations Advisor

POLYTEMS HIR
Bianca FERSINI MASTELLONI - Silvia MARONGIU
06.69923324-066797849
s.marongiu@polytemshir.it

Specialist

Banca Profilo
+39 02.584081

Euronext Growth Advisor

Banca Profilo
Milan, Via Cerva 28
+39 02.584081
svasbiosana@bancaprofilo.it

Media Relations Advisor

POLYTEMS HIR
Paolo SANTAGOSTINO
+393493856585
p.santagostino@polytemshir.it

SVAS BIOSANA S.p.A.

Registro Imprese di
Napoli n.4543/85
n. R.E.A. 393065
C.F. 04720630633
P. I.V.A. 01354901215

Sede Legale

Via M. Perillo, 34
80047
San Giuseppe Vesuviano (NA)
Italy

Corrispondenza

Casella Postale n.91
80049
Somma Vesuviana (NA)
Italy

Direzione ed Uffici

Via Trentola, 7
80049
Somma Vesuviana (NA)
Italy

Contatti

Tel. +390818995411
Fax +390818993922
www.svas.it
svasbiosana@legalmail.it